Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis

JS Katzeff, F Bright, K Phan, JJ Kril, LM Ittner… - Brain, 2022 - academic.oup.com
Frontotemporal dementia refers to a group of neurodegenerative disorders characterized by
behaviour and language alterations and focal brain atrophy. Amyotrophic lateral sclerosis is …

From multi-omics approaches to precision medicine in amyotrophic lateral sclerosis

G Morello, S Salomone, V D'Agata… - Frontiers in …, 2020 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disorder,
caused by the degeneration of upper and lower motor neurons for which there is no truly …

Micro-RNAs shuttled by extracellular vesicles secreted from mesenchymal stem cells dampen astrocyte pathological activation and support neuroprotection in in-vitro …

F Provenzano, S Nyberg, D Giunti, C Torazza, B Parodi… - Cells, 2022 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with no effective cure.
Astrocytes display a toxic phenotype in ALS and contribute to motoneuron (MN) …

Tetracyclines promote survival and fitness in mitochondrial disease models

EA Perry, CF Bennett, C Luo, E Balsa… - Nature …, 2021 - nature.com
Mitochondrial diseases (MDs) are a heterogeneous group of disorders resulting from
mutations in nuclear or mitochondrial DNA genes encoding mitochondrial proteins,. MDs …

Recovery of depleted miR-146a in ALS cortical astrocytes reverts cell aberrancies and prevents paracrine pathogenicity on microglia and motor neurons

M Barbosa, C Gomes, C Sequeira… - Frontiers in Cell and …, 2021 - frontiersin.org
Reactive astrocytes in Amyotrophic Lateral Sclerosis (ALS) change their molecular
expression pattern and release toxic factors that contribute to neurodegeneration and …

Biomarkers for diseases with TDP-43 pathology

P Steinacker, P Barschke, M Otto - Molecular and Cellular Neuroscience, 2019 - Elsevier
The discovery that aggregated transactive response DNA-binding protein 43 kDa (TDP-43)
is the major component of pathological ubiquitinated inclusions in amyotrophic lateral …

[HTML][HTML] A review of biomarkers of amyotrophic lateral sclerosis: a pathophysiologic approach

RS Alshehri, AR Abuzinadah, MS Alrawaili… - International Journal of …, 2024 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by
progressive degeneration of upper and lower motor neurons. The heterogeneous nature of …

Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis

F Verde, I Milone, A Maranzano… - Annals of Clinical …, 2023 - Wiley Online Library
Objective To compare serum levels of the astrocyte biomarker glial fibrillary acidic protein
(GFAP) in patients with amyotrophic lateral sclerosis (ALS) and neurologically healthy …

Blood-based protein biomarkers during the acute ischemic stroke treatment window: a systematic review

J Rahmig, A Chanpura, A Schultz, FC Barone… - Frontiers in …, 2024 - frontiersin.org
Background Rapid and accurate acute ischemic stroke (AIS) diagnosis is needed to
expedite emergent thrombolytic and mechanical thrombectomy treatment. Changes in blood …

Genetic Downregulation of the Metabotropic Glutamate Receptor Type 5 Dampens the Reactive and Neurotoxic Phenotype of Adult ALS Astrocytes

C Torazza, F Provenzano, E Gallia, M Cerminara… - Cells, 2023 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
progressive degeneration of motor neurons (MNs). Astrocytes display a toxic phenotype in …